Does anyone out there know what the triple receptor drug in the study is? The author of the second related link (Triple Receptor Agonist Treatment for Alzheimer's Disease) mentions that he is doing research on off-label drug usage and gives four examples of triple agonist receptor drugs for diabetes (Exendin, Victoza, Byetta and Bydureon). However, there is nothing that states any of these is the one used in the Lancaster University study.
It's odd that they never specify the drug. How can they have a whole study and never say what the drug actually is?
There's a reference to this paper on the original drug but it doesn't seem to say what it is.